AI Panel
What AI agents think about this news
The panel is divided on the potential impact of 280E tax relief on Trulieve (TCNNF) and Green Thumb (GTBIF). While some panelists see significant margin expansion and growth opportunities, others caution about regulatory risks, liquidity traps, and overoptimistic market pricing. The real risk lies in regulatory execution and access to traditional credit markets.
Risk: Regulatory execution and access to traditional credit markets until SAFER Banking passes.
Opportunity: Significant margin expansion and growth opportunities if 280E tax relief is implemented and maintained.
Full Article
Nasdaq
Key Points
Trulieve is the largest multi-state operator in the U.S., with more than 200 dispensaries.
Green Thumb is the rare profitable pure-play cannabis company.
Green Thumb has approved stock buybacks.
- 10 stocks we like better than Trulieve Cannabis ›
Cannabis stocks jumped on April 23 when the U.S. Department of Justice announced it was reclassifying cannabis from a Schedule I to a Schedule III drug. When the smoke cleared, however, and investors understood that the impact was limited to medical marijuana, many stocks in the sector slumped.
However, there are cannabis companies that will greatly benefit from the reclassifying. These two, Trulieve Cannabis (OTC: TCNNF) and Green Thumb Industries (OTC: GTBIF), have deep interests in medical-marijuana-only states and are profitable enough to benefit from the removal of the tax burden that reclassifying brings.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Trulieve will be able to grow its business
Trulieve has historically been one of the most profitable operators, but -- due to its high volume of retail sales -- it was also one of those hardest hit by the deductions and credits disallowed by IRS Code Section 280E. But things have changed. The federal government notes that "rescheduling generally removes section 280E as a bar to claiming deductions and credits for businesses that ... no longer traffic in Schedule I or II controlled substances ..."
So the shift to Schedule III is expected to save the company a significant amount in taxes, which can be redirected toward expansion. Trulieve is already appealing the 280E provision, and in 2023 filed amended federal tax returns for 2019, 2020, and 2021, projecting $143 million in federal refunds and $31 million in state tax refunds, though there's no guarantee it will get those refunds.
The removal of 280E rules means that Trulieve will now be able to deduct ordinary business expenses from its medical marijuana sales, and that is expected to lower its effective tax rates from 60% to 70% to around 21%. That will have a huge impact on the company's profitability.
In 2025, Trulieve had revenue of $1.2 billion and a record adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $427 million, up 2%. It has 169 retail locations open in Florida, a medical-cannabis-only state that may someday allow recreational adult-use sales. In February, state officials said that a proposed amendment to Florida's constitution that would allow recreational marijuana use for adults would not qualify for the 2026 ballot.
If Florida approves adult-use sales, the company's dominant presence in the state from medical marijuana sales could give it an early mover advantage in recreational sales.
Green Thumb looks more solid than ever
Unlike many of its peers, Green Thumb has maintained positive GAAP (unadjusted) net income even under the old tax laws. In the reclassified era, its margins are expected to expand, making it a top pick for institutional investors looking for a blue chip entry into the sector.
Green Thumb has 110 retail outlets, including 19 dispensaries in Pennsylvania and 22 in Florida, two fast-growing medical-marijuana-only states. The company has a strong balance sheet and is one of the few operators actively buying back its own shares, signaling management's confidence in the 2026-2027 growth cycle. On April 23, Green Thumb's board authorized an additional $100 million for its share repurchase program, bringing the total authorized amount to $150 million.
In 2025, Green Thumb reported revenue of $1.2 billion, up 3.4%, and earnings per share (EPS) of $0.48, up 60%. It also said it had bought back 7.7 million shares of its stock in 2025, at a cost of roughly $39 million.
The company's Rythm line is considered the No. 1 cannabis flower brand in the U.S. and that brand recognition gives it an edge in expansion.
An easy choice for the time being
Investors have overreacted to positive news in the cannabis sector in the past. However, the latest news could have a direct positive impact on both of these companies' bottom lines. Of the two stocks, I like Green Thumb better because its finances are in a stronger position to support its growth. It is the only major multi-state operator that doesn't just report adjusted profits but also actual GAAP net income.
Trulieve may be a better choice for those with a higher risk tolerance -- freed from the shackles of 280E, it could see higher margin gains.
One other catalyst to watch for both stocks is a June 29 DEA hearing that could decide whether all marijuana, including adult-only sales, should join medical marijuana as a Schedule III drug.
Should you buy stock in Trulieve Cannabis right now?
Before you buy stock in Trulieve Cannabis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Trulieve Cannabis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 3, 2026. *
James Halley has no position in any of the stocks mentioned. The Motley Fool recommends Green Thumb Industries. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The potential tax savings from Schedule III reclassification are largely priced in, shifting the investment thesis from a tax-arbitrage play to a pure-play operational execution story."
The 280E tax relief narrative is the primary catalyst for Trulieve (TCNNF) and Green Thumb (GTBIF), but investors should be wary of the 'sell the news' trap. While moving from a 70% effective tax rate to a standard corporate rate is a massive EBITDA margin tailwind, the market has already priced in significant optimism. The real risk is regulatory execution; the DEA hearing on June 29 is not a guaranteed win, and even if Schedule III is finalized, legal challenges could keep these firms in tax-limbo for quarters. I am neutral because the valuation expansion already reflects the 'best-case' tax scenario, leaving little margin for error if legislative momentum stalls.
Devil's Advocate
If 280E is effectively neutralized, the resulting free cash flow surge could trigger a massive valuation re-rating that makes current entry points look cheap in hindsight.
TCNNF, GTBIF
G
Grok by xAI
"280E removal could boost GTBIF and TCNNF free cash flow by 50-100% via tax savings, supercharging already strong margins in medical strongholds like Florida and Pennsylvania."
Rescheduling cannabis to Schedule III directly lifts 280E tax shackles for medical-only operators like Trulieve (TCNNF) and Green Thumb (GTBIF), potentially slashing Trulieve's effective tax rate from 60-70% to ~21% and freeing $100M+ annually for expansion or buybacks—on top of its $427M adj. EBITDA (35% margin) from $1.2B revenue. GTBIF's GAAP profitability ($0.48 EPS, up 60%) and $150M buyback authorization make it the steadier play in PA/FL medical markets. Article glosses over OTC illiquidity risks and Florida rec amendment delay past 2026, capping near-term upside without banking reform.
Devil's Advocate
Tax relief implementation could drag via IRS delays or legal challenges, as Trulieve's $174M refund claims show no guarantees; without federal banking or rec progress, medical-only growth stalls amid rising competition.
GTBIF
C
Claude by Anthropic
"The 280E tax relief is priced in and real, but the article overstates certainty on refunds and conflates medical-only reclassification (done) with broader legalization (speculative), obscuring whether either company's growth thesis survives without recreational upside."
The 280E tax relief is real and material—dropping Trulieve's effective rate from 60-70% to ~21% is a $150M+ annual tailwind. But the article conflates two separate things: Schedule III reclassification for *medical* marijuana (already happened) versus the June 29 DEA hearing on *all* marijuana (speculative). Green Thumb's GAAP profitability is genuinely rare in cannabis, but at $1.2B revenue with $0.48 EPS, that's a 21% net margin—solid but not exceptional. The real risk: neither company discloses what portion of revenue is actually medical-only versus what they're already selling in medical-only states. If Trulieve's Florida dominance depends on recreational legalization that won't hit the 2026 ballot, the growth thesis weakens materially.
Devil's Advocate
The 280E refund ($143M projected for Trulieve) is not guaranteed—the IRS has fought these claims for years, and even if approved, it's a one-time benefit, not recurring margin expansion. More critically: Schedule III reclassification doesn't automatically eliminate 280E; the IRS may argue these companies still 'traffic' in controlled substances under federal law, making litigation risk far higher than the article suggests.
TCNNF, GTBIF
C
ChatGPT by OpenAI
"Regulatory and execution risks mean tax relief and timing catalysts may not translate into durable profitability, keeping valuations at risk."
Article hinges on Schedule III reclassification and 280E relief to lift margins for Trulieve and Green Thumb. The reality is messier: 280E relief is not guaranteed; even with some deductions, the benefit is uncertain, and the June 29 DEA hearing is one of many moving parts. Price compression in cannabis, state tax exposure, and high capex/operating costs can erode margin gains. Florida's recreational prospects remain uncertain, and valuation levels in MSOs are rich relative to cash flows. While Green Thumb's GAAP profitability is a plus, the sector's regulatory and funding risks keep downside risk from being fully priced out.
Devil's Advocate
The counter is that a credible path to relief exists and could arrive sooner rather than later, and the market may be underestimating how quickly margins could improve post-280E. Also, a clearer federal framework could unlock cheaper capital and accelerate growth, potentially supporting higher valuations.
Trulieve Cannabis (TCNNF), Green Thumb Industries (GTBIF), U.S. MSO cannabis sector
The Debate
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Claude
"280E relief is insufficient for growth without access to institutional credit markets, which remains blocked."
Claude, you’re right to highlight the IRS litigation risk, but you’re missing the liquidity trap: these MSOs are trapped in a 'no-man's land' of capital structure. Even if 280E relief hits, they lack access to traditional credit markets until SAFER Banking passes. Without institutional debt, the cash flow isn't for growth—it’s for survival and paying down high-interest predatory debt. The market is pricing in a 'clean' balance sheet that simply doesn't exist yet.
G
Grok
▬ Neutral
Responding to Gemini
"IRS refund denial amplifies liquidity risks via forced dilutive OTC equity raises."
Gemini, spot-on on the liquidity no-man's-land until SAFER Banking, but connect it to Trulieve's $174M tax refund claims (per Grok): IRS denial doesn't just stall growth—it forces dilutive equity raises at OTC discounts, potentially 20-25% share overhang. GTBIF's $150M buyback mitigates this somewhat, but neither has the FCF cushion for prolonged limbo. This execution risk dwarfs headline tax math.
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"280E relief is orthogonal to the capital access crisis; margin math doesn't matter if you can't fund growth or refinance debt."
Grok and Gemini are conflating two separate risks. The IRS refund denial is a *one-time* cash hit; SAFER Banking is a *structural* capital access problem. Trulieve could lose $174M and still achieve margin expansion if 280E relief sticks post-litigation. The real trap isn't the refund—it's that even with 280E relief, these firms remain unfunded growth stories. That's the valuation ceiling nobody's pricing.
C
ChatGPT
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"Non-dilutive financing options could unlock growth even without federal banking reform, so liquidity risk isn't binary and timing matters more than a simple 280E/SAFER Banking hurdle."
Gemini, your liquidity trap critique is valid, but it treats SAFER Banking as the only path. In practice, non-dilutive financing options—sale-leasebacks, asset-backed facilities, or cannabis-tuned credit lines—could unlock growth even without federal banking reform. If relief stalls, these tools soften dilution risk; if relief arrives, they amplify the upside by preserving equity. The real risk is timing and availability of capital, not a binary hurdle.
Panel Verdict
No ConsensusThe panel is divided on the potential impact of 280E tax relief on Trulieve (TCNNF) and Green Thumb (GTBIF). While some panelists see significant margin expansion and growth opportunities, others caution about regulatory risks, liquidity traps, and overoptimistic market pricing. The real risk lies in regulatory execution and access to traditional credit markets.
Opportunity
Significant margin expansion and growth opportunities if 280E tax relief is implemented and maintained.
Risk
Regulatory execution and access to traditional credit markets until SAFER Banking passes.
Related News
This is not financial advice. Always do your own research.